<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27860216</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4876</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>172</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of medical genetics. Part C, Seminars in medical genetics</Title>
          <ISOAbbreviation>Am J Med Genet C Semin Med Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway &amp; therapeutic strategies.</ArticleTitle>
        <Pagination>
          <StartPage>402</StartPage>
          <EndPage>421</EndPage>
          <MedlinePgn>402-421</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajmg.c.31531</ELocationID>
        <Abstract>
          <AbstractText>The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signaling pathway plays an essential role in regulation of normal cell growth, metabolism, and survival. Somatic activating mutations in the PI3K/AKT/mTOR pathway are among the most common mutations identified in cancer, and have been shown to cause a spectrum of overgrowth syndromes including PIK3CA-Related Overgrowth Spectrum, Proteus syndrome, and brain overgrowth conditions. Clinical findings in these disorders may be isolated or multiple, including sporadic or mosaic overgrowth (adipose, skeletal, muscle, brain, vascular, or lymphatic), and skin abnormalities (including epidermal nevi, hyper-, and hypopigmented lesions), and have the potential risk of tumorigenesis. Key negative regulators of the PI3K-AKT signaling pathway include PTEN and TSC1/TSC2 and germline loss-of function mutations of these genes are established to cause PTEN Hamartoma Tumor Syndrome and Tuberous Sclerosis Complex. Mosaic forms of these conditions lead to increased activation of PI3K and mTOR at affected sites and there is phenotypic overlap between these conditions. All are associated with significant morbidity with limited options for treatment other than symptomatic therapies and surgeries. As dysregulation of the PI3K/AKT/mTOR pathway has been implicated in cancer, several small molecule inhibitors targeting different components of the PI3K/AKT/mTOR signaling pathway are under clinical investigation. The development of these therapies brings closer the prospect of targeting treatment for somatic PI3K/AKT/mTOR-related overgrowth syndromes. This review describes the clinical findings, gene function and pathogenesis of these mosaic overgrowth syndromes, and presents existing and future treatment strategies to reduce or prevent associated complications of these disorders. © 2016 Wiley Periodicals, Inc.</AbstractText>
          <CopyrightInformation>© 2016 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Keppler-Noreuil</LastName>
            <ForeName>Kim M</ForeName>
            <Initials>KM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parker</LastName>
            <ForeName>Victoria E R</ForeName>
            <Initials>VE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Darling</LastName>
            <ForeName>Thomas N</ForeName>
            <Initials>TN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martinez-Agosto</LastName>
            <ForeName>Julian A</ForeName>
            <Initials>JA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P50 HD055784</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 NS092090</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR000124</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ZIA HG200388-03</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Med Genet C Semin Med Genet</MedlineTA>
        <NlmUniqueID>101235745</NlmUniqueID>
        <ISSNLinking>1552-4868</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006130" MajorTopicYN="N">Growth Disorders</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">PI3K/AKT/mTOR pathway</Keyword>
        <Keyword MajorTopicYN="Y">segmental overgrowth</Keyword>
        <Keyword MajorTopicYN="Y">somatic mosaicism</Keyword>
        <Keyword MajorTopicYN="Y">therapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27860216</ArticleId>
        <ArticleId IdType="mid">NIHMS902445</ArticleId>
        <ArticleId IdType="pmc">PMC5592089</ArticleId>
        <ArticleId IdType="doi">10.1002/ajmg.c.31531</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3843585</ArticleId>
            <ArticleId IdType="pubmed">24261963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander W. Inhibiting the akt pathway in cancer treatment: three leading candidates. Pharm Ther. 2011;36:225–227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3086120</ArticleId>
            <ArticleId IdType="pubmed">21572779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alomari AI, Burrows PE, Lee EY, Hedequist DJ, Mulliken JB, Fishman SJ. CLOVES syndrome with thoracic and central phlebectasia:Increased risk of pulmonary embolism. J Thorac Cardiovasc Surg. 2010;140:459–466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20537357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch EM, Goodman BK, Van Wesep RA, Liaw D, Clarke K, Parsons R, McKusick VA, Geraghty MT. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J Med Genet A. 1997;71:489–493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9286463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assefa G, Alemie B. Tuberous sclerosis complex (TSC) and Klippel-Trenaunay-Weber (KTW) syndromes association of two complete phakomatoses in a single individual. Ethiop Med J. 2010;48:315–320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21280434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aspuria PJ, Tamanoi F. The Rheb family of GTP-binding proteins. J Cell Signal. 2004;16:1105–1112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15240005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP, Statins in lymphangioleiomyomatosis  Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol. 2013;49:704–709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3931105</ArticleId>
            <ArticleId IdType="pubmed">23947572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek ST, Copeland B, Yun E-J, Kwon S-K, Guemez-Gamboa A, Schaffe AE, Kim S, Kang HC, Song S, Mathern GW, Gleeson JG. An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development. Nat Med. 2015;21:1445–1454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4955611</ArticleId>
            <ArticleId IdType="pubmed">26523971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baynam G, Overkov A, Davis M, Mina K, Schofield L, Allcock R, Laing N, Cook M, Dawkins H, Goldblatt J. A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces. Am J Med Genet A. 2015;167:1659–1667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25851998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Amitai D, Halachmi S, Lapidoth M. Are port wines stains a feature of tuberous sclerosis? J Eur Acad Dermatol Venereol. 2011;25:804–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20946584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Augerger P, Tanti JF, Giorgetti-Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366–4372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21540236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biesecker LG, Sapp JC.  Proteus Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet] Seattle (WA): University of Washington Seattle; 2012. Aug 9, pp. 1993–2016. Available from:  http://www.ncbi.nlm.nih.gov/books/NBK99495/</Citation>
        </Reference>
        <Reference>
          <Citation>Boronat S, Caruso P, Thiele EA. Absence of subependymal nodules in patients with tubers suggests possible neuroectodermal mosaicism in tuberous sclerosis complex. Dev Med Child Neurol. 2014;56:1207–1211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24954233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler MG, Dasouki MJ, Zhou X-P, Talebizaded Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarsk R, Eng C. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet. 2005;42:318–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736032</ArticleId>
            <ArticleId IdType="pubmed">15805158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448:439–444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17611497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caux F, Plauchu H, Chibon F, Faivre L, Fain O, Vabres P, Bonnet F, Selma ZB, Laroche L, Gerard M, Longy M. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet. 2007;15:767–773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17392703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatterjee S, Mukherjee SB, Mendiratta V, Aneja S. Sturge Weber-Like Gyral Calcification Seen in Tuberous Sclerosis Complex 1. J Child Neurol. 2015;30:1070–1074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25117416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen ZH, Zhu M, Yang J, Liang H, He J, He S, Wang P, Kang X, McNutt MA, Yin Y, Shen WH. PTEN interacts with histone H1 and controls chromatin condensation. Cell Rep. 2014;8:2003–2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4201947</ArticleId>
            <ArticleId IdType="pubmed">25199838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Citraro R, Leo A, Constanti A, Russo E, De Sarro G. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharm Res. 2016;107:333–343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27049136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crino PB. mTOR: A pathogenic signaling pathway in developmental brain malformations. Trends Mol Med. 2011;17:734–742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21890410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013;23:53–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23317514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crino PB, Aronica E, Baltuch G, Nathanson KL. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurol. 2010;74:1716–1723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2882213</ArticleId>
            <ArticleId IdType="pubmed">20498439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14:733–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26067126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011;23:744–755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21963299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Gama AM, Geng Y, Couto JA, Martin B, Boyle, LaCoursiere CM, Hossain A, Hatem NE, Barry BJ, Kwiatkowski DJ, Vinters HV, Barkovich AJ, Shendure J, Mathern GW, Walsh CA, Poduri A. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol. 2015;77:720–725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4471336</ArticleId>
            <ArticleId IdType="pubmed">25599672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DiMario FJ, Jr, Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. Pediatr Clin North Am. 2015;62:633–648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26022167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med. 2013;5:196ra99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3935768</ArticleId>
            <ArticleId IdType="pubmed">23903756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eng C.  PTEN Hamartoma Tumor Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet] Seattle (WA): University of Washington, Seattle; 2001. Nov 29, pp. 1993–2016. [Updated 2016 Jun2] Available from:  http://www.ncbi.nlm.nih.gov/books/NBK1488/</Citation>
        </Reference>
        <Reference>
          <Citation>Foster JG, Blunt MD, Carter E, Ward SG. Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies. Pharmacol Rev. 2012;64:1027–1054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23023033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ergün R, Okten AI, Yaman M, Gezici AR, Taşkin Y. Subependymal giant-cell astrocytoma associated with tuberous sclerosis: case report. Neurosurg Rev. 1998;21:185–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9795959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flum AS, Hamoui N, Said MA, Yang XJ, Casalino DD, McGuire BB, Perry KT, Nadler RB. Update on the Diagnosis and Management of Renal Angiomyolipoma. J Urol. 2015;195:834–846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26612197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franz DN. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics. 2013;7:211–221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3797614</ArticleId>
            <ArticleId IdType="pubmed">24143074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Getz SA, DeSpenza T, Li M, Luikart BW. Rapamycin prevents, but does not reverse, aberrant migration in Pten knockout neurons. Neurobiol Dis. 2016;93:12–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5409093</ArticleId>
            <ArticleId IdType="pubmed">26992888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goffin A, Hoefsloot LH, Bosgoed E, Swillen A, Fryns JP. PTEN mutation in a family with Cowden syndrome and autism. Am J Med Genet A. 2001;105:521–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11496368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM. A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity. Cancer Discov. 2014;4:554–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4012430</ArticleId>
            <ArticleId IdType="pubmed">24631838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gripp KW, Baker L, Kandula V, Conard K, Scavina M, Napoli JA, Griffin GC, Thacker M, Knox RG, Clark GR, Parker VER, Semple R, Mirzaa G, Keppler-Noreuil KM. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation. Am J Med Genet A. 2016;170:2559–2569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5514817</ArticleId>
            <ArticleId IdType="pubmed">27191687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerrini R, Duchowny M, Jayakar P, Krsek P, Kahane P, Tassi L, Melani F, Polster T, Andre VM, Cepeda C, Krueger DA, Cross JH, Spreafico R, Cosottini M, Gotman J, Chassoux F, Ryvlin P, Bartolomei F, Bernasconi A, Stefan H, Miller I, Devaux B, Najm I, Giordano F, Vonck K, Barba C, Blumcke I. Diagnostic methods and treatment options for focal cortical dysplasia. Epilepsia. 56:1669–1686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26434565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008;8:733–740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2831175</ArticleId>
            <ArticleId IdType="pubmed">19075596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Happle R.  Mosaicism in Human Skin. Understanding Nevi, Nevoid Skin Disorders, and Cutaneous Neoplasia. Springer-Verlag; Berlin Heidelberg: 2014. Two Major Categories of Mosaicism; pp. 13–37.</Citation>
        </Reference>
        <Reference>
          <Citation>Hardt M, Chantaravisoot N, Tamanoi F. Activating mutations of TOR (target of rapamycin) Genes Cells. 2011;16:141–151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3116645</ArticleId>
            <ArticleId IdType="pubmed">21210909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmes D. PI3K pathway inhibitors approach junction. Nat Rev. 2011;10:563–564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21804582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009;37:217–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2778026</ArticleId>
            <ArticleId IdType="pubmed">19143635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubbard PA, Moody CL, Murali R. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Front Physiol. 2014;5:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4267178</ArticleId>
            <ArticleId IdType="pubmed">25566081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJ, et al.  An activating mutation of AKT2 and human hypoglycemia. Science. 2011;334:474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3204221</ArticleId>
            <ArticleId IdType="pubmed">21979934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iacoba I, Burrows PH, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011;57:321–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21360661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol. 2002;4:648–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jóźwiak S, Mandera M, Młynarski W. Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. Semin Pediatr Neurol. 2015;22:274–281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26706014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VER, Blumhorst C, Darling T, Tosi LL, Huson SM, Whitehouse RW, Jakkula E, Grant I, Balasubramanian M, Chandler KE, Fraser JL, Gucev Z, Crow YJ, Brennan LM, Clark R, Sellars EA, Pena LDM, Krishnamurty V, Shuen A, Braverman N, Cunningham ML, Sutton VR, Tasic V, Graham JM, Geer J, Henderson A, Semple RK, Biesecker LG. Clinical Delineation and Natural History of the PIK3CA-Related Overgrowth Spectrum. Am J Med Genet A. 2014;164:1713–1733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4320693</ArticleId>
            <ArticleId IdType="pubmed">24782230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG. PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis and evaluation. Am J Med Genet A. 2015;167:287–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4480633</ArticleId>
            <ArticleId IdType="pubmed">25557259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keppler-Noreuil KM, Baker EH, Sapp JC, Lindhurst MJ, Biesecker LG. Somatic AKT1 mutations cause meningiomas Colocalizing with a characteristic pattern of cranial hyperostosis. Am J Med Genet A. 2016;170:2605–2610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5580816</ArticleId>
            <ArticleId IdType="pubmed">27550858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein S, Sharifi-Hannauer P, Martinez-Agosto JA. Macrocephaly as a Clinical Indicator of Genetic Subtypes in Autism. Autism Res. 2013;6:51–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3581311</ArticleId>
            <ArticleId IdType="pubmed">23361946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801–1811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21047224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krueger DA, Northrup H. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49:255–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4058297</ArticleId>
            <ArticleId IdType="pubmed">24053983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects. Cell Cycle. 2009;8:403–413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718392</ArticleId>
            <ArticleId IdType="pubmed">19177005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP, Warman ML. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 2012;90:1108–1115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3370283</ArticleId>
            <ArticleId IdType="pubmed">22658544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamming D, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013;123:980–989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3582126</ArticleId>
            <ArticleId IdType="pubmed">23454761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012;44:941–945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4417942</ArticleId>
            <ArticleId IdType="pubmed">22729223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leslie NR, Longy M. Inherited PTEN mutations and the prediction of phenotype. Semin Cell Dev Biol. 2016;52:30–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26827793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leventer RJ, Scerri T, Marsh AP, Pope K, Gillies G, Maixner W, MacGregor D, Harvey AS, Delatycki MB, Amor DJ, Crino P, Bahlo M, Lockhart PJ. Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR. Neurol. 2015;84:2029–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4442098</ArticleId>
            <ArticleId IdType="pubmed">25878179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Wang G. Computer-Aided Targeting of the PI3K/Akt/mTOR pathway: Toxicity Reduction and Therapeutic Opportunities. Int J Mol Sci. 2014;15:18856–18891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4227251</ArticleId>
            <ArticleId IdType="pubmed">25334061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;67:1596–1606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3532946</ArticleId>
            <ArticleId IdType="pubmed">23094721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim JS, Kim WI, Kang HC, Kim SH, Park AH, Park EK, Cho YW, Kim S, Kim HM, Kim JA, Kim J, Rhee H, Kang SG, Kim HD, Kim D, Kim DS, Lee JH. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med. 2015;21:395–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25799227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O’Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome. N Engl J Med. 2011;365:611–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3170413</ArticleId>
            <ArticleId IdType="pubmed">21793738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindhurst MJ, Parker VER, Payne F, Sapp JC, Rudge S, Harris J, Witdowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Halliwell T, O’Rahilly SO, Savage DB, Wakelam MJO, Barroso I, Biesecker LG, Semple RK. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations inPIK3CA. Nat Genet. 2012;44:928–933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3461408</ArticleId>
            <ArticleId IdType="pubmed">22729222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ljungberg MC, Bhattacharjee MB, Lu Y, Armstrong DL, Yoshor D, Swann JW, Sheldon M, D’Arcangelo G. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol. 2006;60:420–429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16912980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loconte DC, Grossi V, Bozzao C, Forte G, Bagnulo R, Stella A, Lestella P, Cutrone M, Benedicenti F, Susca FC, Petruno M, Varvara D, Germani A, Chessa L, Laforgia N, Tenconi R, Simone C, Resta N. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors. PLoS One. 2015;10:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4411002</ArticleId>
            <ArticleId IdType="pubmed">25915946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005;15:702–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15854902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB, Rahbar R, Spencer SA, Trenor CC, 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A, Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015;166:1048–1054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4498659</ArticleId>
            <ArticleId IdType="pubmed">25681199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R, Hirawat S. PI3K inhibitors as new cancer therapetuics: implications for clinical trial design. Onco Targets Ther. 2015;9:203–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4708174</ArticleId>
            <ArticleId IdType="pubmed">26793003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7:1851–1863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18606717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway–beyond rapalogs. Oncotarget. 2010;1:530–543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3248125</ArticleId>
            <ArticleId IdType="pubmed">21317449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5:357–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18431376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medvetz D, Priolo C, Henske EP. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift. Mol Cancer Res. 2015;13:3–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4312527</ArticleId>
            <ArticleId IdType="pubmed">25298408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mester J, Eng C. When Overgrowth Bumps Into Cancer: The PTEN-Opathies. Am J Med Genet C, Semin Med Genet. 2013;163:114–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23613428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirzaa GM, Conway RL, Gripp KW, Lerman-Sagie T, Siegel DH, deVries LS, Lev D, Kramer N, Hopkins E, Graham JM, Jr, Dobyns WB. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am J Med Genet A. 2012;158:269–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22228622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirzaa GM, Parry DA, Fry AE, Giamanco KA, Schwartzentruber J, Vanstone M, Logan CV, Roberts N, Johnson CA, Singh S, Kholmanskikh SS, Adams C, Hodge RD, Hevner RF, Bonthron DT, Braun KP, Faivre L, Rivière JB, St-Onge J, Gripp KW, Mancini GM, Pang K, Sweeney E, van Esch H, Verbeek N, Wieczorek D, Steinraths M, Majewski J, FORGE Canada Consortium. Boycott KM, Pilz DT, Ross ME, Dobyns WB, Sheridan EG. De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome. Nat Genet. 2014;46:510515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4004933</ArticleId>
            <ArticleId IdType="pubmed">24705253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirzaa GM, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B, Kircher M, Olds C, Juusola J, Collin S, Park K, Carter M, Glass I, Krageloh-Mann I, Chitayat D, Parikh AS, Bradshaw R, Torti E, Braddock S, Burke L, Ghedia S, Stephan M, Stewart F, Prasad C, Napier M, Saitta S, Straussberg R, Gabbett M, O’Connor BC, Keegan CE, Yin LJ, Lai AHM, Martin N, McKinnon M, Addor MC, Boccuto L, Schwartz CE, Lanoei A, Conway RL, Devriendt K, Tatton-Brown K, Pierpont ME, Painter M, Worgan L, Reggin J, Hennekam R, Tsuchiya K, Pritchard CC, Aracena M, Gripp KW, Cordisco M, Esch HV, Garavelli L, Curry C, Goriely A, Kayserilli H, Shendure J, Graham J, Guerrini R, Dobyns WB. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. 2016  http://dx.doi.org/10.1172/jci.insight.87623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.87623</ArticleId>
            <ArticleId IdType="pmc">PMC5019182</ArticleId>
            <ArticleId IdType="pubmed">27631024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirzaa GM, Campbell CD, Solovieff N, Goold CP, Jansen LA, Menon S, Timms AE, Conti V, Biag JD, Olds C, Boyle EA, Collins S, Ishak G, Poliachik SL, Girisha KM, Yeung KS, Chung BH, Rahikkala E, Gunter SA, McDaniel SS, Macmurdo CF, Bernstein JA, Martin B, Leary RJ, Mahan S, Liu S, Weaver M, Dorschner MO, Jhangiani S, Muzny DM, Boerwinkle E, Gibbs RA, Lupski JR, Shendure J, Saneto RP, Novotny EJ, Wilson CJ, Sellers WR, Morrissey MP, Hevner RF, Ojemann JG, Guerrini R, Murphy LO, Winckler W, Dobyns WB. Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism. JAMA Neurol. 2016;73:836–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4979321</ArticleId>
            <ArticleId IdType="pubmed">27159400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mroske C, Rasmussen K, Shinde DN, Huether R, Powis Z, Lu HM, Baxter RM, McPherson E, Tang S. Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities. BMC Med Genet. 2015;16:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4635597</ArticleId>
            <ArticleId IdType="pubmed">26542245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakashima M, Saitsu H, Takei N, Tohyama J, Kato M, Kitaura H, Shiina M, Shirozu H, Masuda H, Watanabe K, Ohba C, Tsurusaki Y, Miyake N, Zheng Y, Sato T, Takebayashi H, Ogata K, Kameyama S, Kakita A, Matsumoto N. Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann Neurol. 2015;78:375–386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26018084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49:243–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4080684</ArticleId>
            <ArticleId IdType="pubmed">24053982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. 2013  http://meetinglibrary.asco.org/content/131-132:1-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3821994</ArticleId>
            <ArticleId IdType="pubmed">23714559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paller AS. Piecing together the puzzle of cutaneous mosaicism. J Clin Invest. 2004;114:1407–1409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC526027</ArticleId>
            <ArticleId IdType="pubmed">15545989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013;12:177–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23252795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, Lunardi A, Webster K, Ng C, Newton RH, Knoblauch N, Guarnerio J, Ito K, Turka LA, Beck AH, Pinton P, Bronson RT, Wei W, Pandolfi PP. Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function. Cell. 2014;157:595–610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4098792</ArticleId>
            <ArticleId IdType="pubmed">24766807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patil VV, Guzman M, Carter AN, Rathore G, Yoshor D, Curry D, Wilfong A, Agadi S, Swann JW, Adesina AM, Bhattacharjee MB, Anderson AE. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia. Neuropathology. 2016;36:146–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5458727</ArticleId>
            <ArticleId IdType="pubmed">26381727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrulea MS, Plantinga TS, Smit JW, Georgescu CE, Netea-Maier RT. PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma. Cancer Treat Rev. 2015;41:707–713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26138515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012;74:41–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3460551</ArticleId>
            <ArticleId IdType="pubmed">22500628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3995050</ArticleId>
            <ArticleId IdType="pubmed">24782981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, Ezaki M. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet. 2012;22:444–451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3542862</ArticleId>
            <ArticleId IdType="pubmed">23100325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riviere JB, Mirzaa GM, O’Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL, Finding of Rare Disease Genes (FORGE) Canada Consortium. Majewski J, Bulman DE, O’Driscoll M, Shendure J, Graham JM, Jr, Boycott KM, Dobyns WB. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012;44:934–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3408813</ArticleId>
            <ArticleId IdType="pubmed">22729224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Escudero I, Oliver MD, Andres-Pons A, Molina M, Cid VJ, Pulido R. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum Mol Genet. 2011;20:4132–4142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21828076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16915295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadowski K, Kotulska K, Jóźwiak S. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep. 2016;68:536–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26891243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15016963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17:596–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16226444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxena A, Sampson JR. Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments. Semin Neurol. 2015;35:269–276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26060906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scerri T, Riseley JR, Gillies G, Pope K, Burgess R, Mandelstam SA, Dibbens L, Chow CW, Maixner W, Harvey AS, Amor DJ, Delatycki MB, Crino PB, Bahlo M, Lockhart PJ, Leventer RJ. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann Clin Transl Neurol. 2015;2:575–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4435711</ArticleId>
            <ArticleId IdType="pubmed">26000329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid GL, Kassner F, Uhlig HH, Korner A, Kratzsch J, Handel N, Zepp F-P, Kowalzik F, Laner A, Starke S, Wilhelm FK, Schuster S, Viehweger A, Hirsch W, Kiess W, Garten A. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatr Res. 2014;75:527–534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24366516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seibert D, Hong CH, Takeuchi F, Olsen C, Hathaway O, Moss J, Darling TN. Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences. Ann Intern Med. 2011;154:806–813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367307</ArticleId>
            <ArticleId IdType="pubmed">21690595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature. 2006;441:424–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16724053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM, Pevsner J. Surge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368:1971–1979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3749068</ArticleId>
            <ArticleId IdType="pubmed">23656586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sim JC, Scerri T, Fanjul-Fernández M, Riseley JR, Gillies G, Pope K, van Roozendaal H, Heng JI, Mandelstam SA, McGillivray G, MacGregor D, Kannan L, Maixner W, Harvey AS, Amor DJ, Delatycki MB, Crino PB, Bahlo M, Lockhart PJ, Leventer RJ. Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3. Ann Neurol. 2016;79:132–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26285051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soeiro E, Sá M, Moldovan O, Sousa AB. Macrodactyly in tuberous sclerosis complex: Case report and review of the literature. Am J Med Genet A. 2016;170:1903–1907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27112935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP. Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner. Cell. 2011;144:187–199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3249980</ArticleId>
            <ArticleId IdType="pubmed">21241890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taveira-DaSilva AM, Moss J. Management of lymphangioleiomyomatosis. F1000Prime Rep. 2014;6:116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4251421</ArticleId>
            <ArticleId IdType="pubmed">25580270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tilot AK, Frazier TW, Eng Charis. Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder. Neurotherapeutics. 2015;12:609–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4489960</ArticleId>
            <ArticleId IdType="pubmed">25916396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tosi LL, Sapp JC, Allen ES, O’Keefe RJ, Biesecker LG. Assessment and management of the orthopedic and other complications of Proteus syndrome. J Child Orthop. 2011;5:319–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3179535</ArticleId>
            <ArticleId IdType="pubmed">23024722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trauner MA, Ruben BS, Lynch PJ. Segmental tuberous sclerosis presenting as unilateral facial angiofibromas. J Am Acad Dermatol. 2003;49:S164–S166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12894111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Troost BT, Savino PJ, Lozito JC. Tuberous sclerosis and Klippel-Trenaunay-Weber syndromes. Association of two complete phakomatoses in a single individual. J Neurol Neurosurg Psych. 1975;38:500–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC492003</ArticleId>
            <ArticleId IdType="pubmed">168320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyburczy ME, Wang JA, Li S, Thangapazham R, Chekaluk Y, Moss J, Kwiatkowski DJ, Darling TN. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet. 2014;23:2023–2029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3959815</ArticleId>
            <ArticleId IdType="pubmed">24271014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyburczy ME, Jozwiak S, Malinowska IA, Chekaluk Y, Pugh TJ, Wu CL, Nussbaum RL, Seepo S, Dzik T, Kotulska K, Kwiatkowski DJ. A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum Mol Genet. 2015a;24:1836–1842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4355019</ArticleId>
            <ArticleId IdType="pubmed">25432535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, Lin L, Krueger D, Franz DN, Thiele EA, Sahin M, Kwiatkowski DJ. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015b;11:e1005637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4634999</ArticleId>
            <ArticleId IdType="pubmed">26540169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13:195–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22358332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short MP, Haines JH, Jozwiak S, Kwiatkowski DJ. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997:277805–277808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9242607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet. 1998;7:1053–1057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9580671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verhoef S, Bakker L, Tempelaars AM, Hesseling-Janssen AL, Mazurczak T, Jozwiak S, Fois A, Bartalini G, Zonnenberg BA, van Essen AJ, Lindhout D, Halley DJ, van den Ouweland AM. High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet. 1999;64:1632–1637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1377905</ArticleId>
            <ArticleId IdType="pubmed">10330349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vivanco I, Sawyers CL. The Phosphatidlinositol-3-kinase-AKT pathway in Human Cancer. Nat Rev. 2002;2:489–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12094235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Wu J, Zhang W, Zhi Y, Wu Y, Jiang R, Yang R. Effects of aspirin on the ERK and PI3K/Akt signaling pathways in rats with acute pulmonary embolism. Mol Med Rep. 2013;8:1465–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24026640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weigelt B, Downward J. Genomic determinants of PI3K pathway inhibitor response in cancer. Front Oncol. 2012;2:1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431500</ArticleId>
            <ArticleId IdType="pubmed">22970424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong Michael. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia. 2010;51:27–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3022513</ArticleId>
            <ArticleId IdType="pubmed">19817806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong M. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations. Exp Neurol. 2013;244:22–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3265661</ArticleId>
            <ArticleId IdType="pubmed">22015915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16469695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasin SA, Ali AM, Tata M, Picker SR, Anderson GW, Latimer-Bowman E, Nicholson SL, Harkness W, Cross JH, Paine SM, Jacques TS. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis. Acta Neuropathol. 2013;126:207–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23728790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Savage RE, Eathiraj S, Meade J, Wick MJ, Hall T, Abbadessa G, Schwartz B. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479. doi: 10.1371/journal.pone.0140479. 2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0140479</ArticleId>
            <ArticleId IdType="pmc">PMC4607407</ArticleId>
            <ArticleId IdType="pubmed">26469692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–5510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3398461</ArticleId>
            <ArticleId IdType="pubmed">18794884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou HY, Huang SL. Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer. 2012;31:8–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3249493</ArticleId>
            <ArticleId IdType="pubmed">22059905</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
